GLP1R and obesity due to melanocortin 4 receptor deficiency: As mentioned earlier, although many pharmaceutical companies are competing in the rapidly growing obesity-drug market, when it comes to oral formulations they typically focus on small-molecule (biased) GLP-1 analogs.